Rhumbline Advisers Foghorn Therapeutics Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 33,335 shares of FHTX stock, worth $261,346. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,335

Previous 35,910 7.17%

Holding current value

$261,346

Previous $206,000 50.49%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$4.8 - $9.99 $12,360 - $25,724	-2,575 Reduced 7.17%	33,335 $310,000
Q2 2024 Aug 01, 2024	BUY	$5.05 - $8.0 $46,313 - $73,368	9,171 Added 34.3%	35,910 $206,000
Q1 2024 May 09, 2024	BUY	$2.82 - $7.94 $2,193 - $6,177	778 Added 3.0%	26,739 $179,000
Q4 2023 Feb 08, 2024	SELL	$2.94 - $6.76 $1,367 - $3,143	-465 Reduced 1.76%	25,961 $167,000
Q3 2023 Nov 09, 2023	BUY	$5.0 - $9.87 $4,995 - $9,860	999 Added 3.93%	26,426 $132,000
Q2 2023 Aug 08, 2023	BUY	$5.37 - $8.84 $606 - $998	113 Added 0.45%	25,427 $179,000
Q1 2023 May 11, 2023	SELL	$4.66 - $8.99 $2,036 - $3,928	-437 Reduced 1.7%	25,314 $157,000
Q4 2022 Feb 14, 2023	BUY	$5.44 - $9.46 $5,293 - $9,204	973 Added 3.93%	25,751 $164,000
Q3 2022 Nov 10, 2022	BUY	$7.52 - $18.01 $12,791 - $30,635	1,701 Added 7.37%	24,778 $213,000
Q2 2022 Aug 11, 2022	BUY	$8.48 - $16.84 $3,400 - $6,752	401 Added 1.77%	23,077 $314,000
Q1 2022 May 12, 2022	BUY	$8.87 - $22.1 $28,588 - $71,228	3,223 Added 16.57%	22,676 $345,000
Q4 2021 Feb 10, 2022	BUY	$10.79 - $22.87 $10,563 - $22,389	979 Added 5.3%	19,453 $445,000
Q3 2021 Nov 12, 2021	BUY	$8.33 - $15.02 $23,448 - $42,281	2,815 Added 17.98%	18,474 $257,000
Q2 2021 Aug 05, 2021	BUY	$9.32 - $13.26 $145,941 - $207,638	15,659 New	15,659 $167,000

Others Institutions Holding FHTX

# of Institutions

Shares Held

33.3M

Call Options Held

8.7K

Put Options Held

2.4K

View Full List

About Foghorn Therapeutics Inc.

Ticker FHTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,637,400
Market Cap $326M
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...

More about FHTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Foghorn Therapeutics Inc. Transaction History